RLA-DR Antibodies

Santa Cruz Biotechnology offers a broad range of RLA-DR monoclonal antibodies for research focused on understanding RLA-DR protein function. RLA-DR monoclonal antibodies are validated for multiple applications, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). RLA-DR, a member of the major histocompatibility complex (MHC) class II molecules, plays a crucial role in the immune response by presenting antigens to CD4+ T cells. The RLA-DR protein is essential for the activation of the adaptive immune system and is involved in various autoimmune diseases and transplant rejection processes. Understanding the function and regulation of RLA-DR is vital for developing therapeutic strategies targeting immune-related conditions. RLA-DR monoclonal antibodies enable precise detection and analysis of RLA-DR expression patterns in different cell types and tissues. Researchers can utilize RLA-DR monoclonal antibodies to investigate cellular localization, protein-protein interactions, and expression levels under various experimental conditions. Santa Cruz Biotechnology monoclonal antibodies for RLA-DR support researchers worldwide in advancing our understanding of immune system regulation and disease mechanisms.